These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142 [TBL] [Abstract][Full Text] [Related]
4. Linezolid: a new antibiotic for newborns and children? Cuzzolin L; Fanos V J Chemother; 2006 Dec; 18(6):573-81. PubMed ID: 17267334 [TBL] [Abstract][Full Text] [Related]
5. Linezolid: in infants and children with severe Gram-positive infections. Lyseng-Williamson KA; Goa KL Paediatr Drugs; 2003; 5(6):419-29; discussion 430-1. PubMed ID: 12765493 [TBL] [Abstract][Full Text] [Related]
6. Linezolid for the treatment of resistant gram-positive cocci. Bain KT; Wittbrodt ET Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064 [TBL] [Abstract][Full Text] [Related]
8. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141 [TBL] [Abstract][Full Text] [Related]
9. Use of linezolid in infants and children: a retrospective multicentre study of the Italian Society for Paediatric Infectious Diseases. Garazzino S; Krzysztofiak A; Esposito S; Castagnola E; Plebani A; Galli L; Cellini M; Lipreri R; Scolfaro C; Bertaina C; Calitri C; Bozzola E; Lancella L; Quondamcarlo A; Bosis S; Pugni L; Losurdo G; Soresina A; De Gaudio M; Mariotti I; Mancini L; Gabiano C; Tovo PA J Antimicrob Chemother; 2011 Oct; 66(10):2393-7. PubMed ID: 21764828 [TBL] [Abstract][Full Text] [Related]
10. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Rubinstein E; Isturiz R; Standiford HC; Smith LG; Oliphant TH; Cammarata S; Hafkin B; Le V; Remington J Antimicrob Agents Chemother; 2003 Jun; 47(6):1824-31. PubMed ID: 12760854 [TBL] [Abstract][Full Text] [Related]
11. Linezolid for the treatment of complicated skin and skin structure infections in children. Yogev R; Patterson LE; Kaplan SL; Adler S; Morfin MR; Martin A; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S172-7. PubMed ID: 14520143 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of linezolid in liver transplant patients. Radunz S; Juntermanns B; Kaiser GM; Treckmann J; Mathe Z; Paul A; Saner FH Transpl Infect Dis; 2011 Aug; 13(4):353-8. PubMed ID: 21355969 [TBL] [Abstract][Full Text] [Related]
13. Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review. Kocher S; Müller W; Resch B Int J Antimicrob Agents; 2010 Aug; 36(2):106-10. PubMed ID: 20605418 [TBL] [Abstract][Full Text] [Related]
14. Use of linezolid in pediatrics: a critical review. Dotis J; Iosifidis E; Ioannidou M; Roilides E Int J Infect Dis; 2010 Aug; 14(8):e638-48. PubMed ID: 20106697 [TBL] [Abstract][Full Text] [Related]
15. Experience with linezolid therapy in children with osteoarticular infections. Chen CJ; Chiu CH; Lin TY; Lee ZL; Yang WE; Huang YC Pediatr Infect Dis J; 2007 Nov; 26(11):985-8. PubMed ID: 17984803 [TBL] [Abstract][Full Text] [Related]
18. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens]. Manfredi R Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159 [TBL] [Abstract][Full Text] [Related]
19. Use of linezolid in children: an overview of recent advances. Velissariou IM Expert Rev Anti Infect Ther; 2006 Dec; 4(6):947-52. PubMed ID: 17181410 [TBL] [Abstract][Full Text] [Related]